Back | Next |
home / stock / rvnc / rvnc message board
Subject | By | Source | When |
---|---|---|---|
If you watch the latest episode of | Emannow | investorshub | 04/18/2023 11:35:02 PM |
Traditionally, the FDA limited the amount of neurotoxin | iwfal | investorshub | 04/18/2023 11:04:09 PM |
The average Botox patient is treated 1.8 times | iwfal | investorshub | 04/18/2023 10:51:11 PM |
Toxin Competitors Focus on Doubling Dosing | Emannow | investorshub | 04/18/2023 10:38:27 PM |
The average Botox patient is treated 1.8 times | Emannow | investorshub | 04/18/2023 10:18:39 PM |
Another interesting point on the call today was | Emannow | investorshub | 04/18/2023 10:05:00 PM |
Yes, good webcast and I can also appreciate | Mufaso | investorshub | 04/18/2023 9:59:36 PM |
In speaking with other practices, most are loving | iwfal | investorshub | 04/18/2023 9:57:54 PM |
Def can understand your point of view, but | stocksrising | investorshub | 04/18/2023 9:27:01 PM |
Webcast was informative. Interesting how he referenced that | boraborak38 | investorshub | 04/18/2023 7:24:47 PM |
Yes sir, think we heard timeframe of between | stocksrising | investorshub | 04/18/2023 6:24:22 PM |
Fosun reported last week positive BLA from Chinese | DewDiligence | investorshub | 04/18/2023 6:01:28 PM |
Decent call between Tobin & Serge.. | stocksrising | investorshub | 04/18/2023 5:45:21 PM |
Will be jumping on CCall, will comment if | stocksrising | investorshub | 04/18/2023 2:51:54 PM |
Hugel has gotten 2nd CRL because of site inspection. | RVNCfan | investorshub | 04/18/2023 4:46:16 AM |
I knew about the reduced diffusion and the | mouton29 | investorshub | 04/17/2023 9:45:15 PM |
The rumor is Daxi sales in Q1 were | Emannow | investorshub | 04/17/2023 9:39:04 PM |
Re: Daxxifys longevity MoA | DewDiligence | investorshub | 04/17/2023 9:12:03 PM |
Been around the markets for 50+ years | Bio_pete | investorshub | 04/17/2023 9:09:35 PM |
Re: Dr. Kane podcast. He said two | mouton29 | investorshub | 04/17/2023 8:53:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...